US 12,258,627 B2
Kelch domain containing 7B (KLHDC7B) variants and uses thereof
Kavita Praveen, Tarrytown, NY (US); Giovanni Coppola, Tarrytown, NY (US); Manuel Allen Revez Ferreira, Tarrytown, NY (US); Lauren Gurski, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); Meghan Drummond Samuelson, Tarrytown, NY (US); and Goncalo Abecasis, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Apr. 19, 2023, as Appl. No. 18/303,193.
Application 18/303,193 is a continuation of application No. 17/307,653, filed on May 4, 2021, granted, now 11,674,177.
Claims priority of provisional application 63/087,245, filed on Oct. 4, 2020.
Claims priority of provisional application 63/020,746, filed on May 6, 2020.
Prior Publication US 2023/0366024 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6876 (2018.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)
CPC C12Q 1/6874 (2013.01) [C12Q 1/6851 (2013.01); C12Q 1/6876 (2013.01); G01N 33/6818 (2013.01); A61K 38/00 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method of treating a subject having hearing loss with a therapeutic agent that treats or inhibits hearing loss, wherein the subject has been determined to have a Kelch Domain Containing 7B (KLHDC7B) missense variant nucleic acid molecule encoding KLHDC7B K181fs or KLHDC7B G302fs.